JP6647302B2 - Sfrp5由来ペプチド断片およびそれを含有する皮膚美白用化粧料組成物 - Google Patents
Sfrp5由来ペプチド断片およびそれを含有する皮膚美白用化粧料組成物 Download PDFInfo
- Publication number
- JP6647302B2 JP6647302B2 JP2017527690A JP2017527690A JP6647302B2 JP 6647302 B2 JP6647302 B2 JP 6647302B2 JP 2017527690 A JP2017527690 A JP 2017527690A JP 2017527690 A JP2017527690 A JP 2017527690A JP 6647302 B2 JP6647302 B2 JP 6647302B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide fragment
- sfrp5
- cosmetic composition
- present
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000007079 Peptide Fragments Human genes 0.000 title claims description 55
- 108010033276 Peptide Fragments Proteins 0.000 title claims description 55
- 239000002537 cosmetic Substances 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 22
- 101000684730 Homo sapiens Secreted frizzled-related protein 5 Proteins 0.000 title 1
- 102100023744 Secreted frizzled-related protein 5 Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 102000005698 Frizzled receptors Human genes 0.000 claims description 18
- 108010045438 Frizzled receptors Proteins 0.000 claims description 18
- 208000012641 Pigmentation disease Diseases 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 13
- 230000002087 whitening effect Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 description 39
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 210000002752 melanocyte Anatomy 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 102000015735 Beta-catenin Human genes 0.000 description 16
- 108060000903 Beta-catenin Proteins 0.000 description 16
- 102000003425 Tyrosinase Human genes 0.000 description 16
- 108060008724 Tyrosinase Proteins 0.000 description 16
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 15
- 101710200814 Melanotropin alpha Proteins 0.000 description 15
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 15
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 14
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 14
- 108050003627 Wnt Proteins 0.000 description 14
- 102000013814 Wnt Human genes 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 7
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 7
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 7
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 7
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 7
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 7
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 5
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 5
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 5
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 5
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101710181403 Frizzled Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009013 pigment accumulation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010384 proximity ligation assay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Description
自動ペプチド合成機(PeptrEx-R48、Peptron社製、テジョン、大韓民国)を用いて、配列番号1〜9のペプチド断片をFMOC固相法で合成した。合成したペプチド断片は、C18分析用RPカラム(資生堂カプセルパック)を使用した逆相高速液体クロマトグラフィー(逆相HPLC)(Prominence LC-20AB、島津製作所製、日本)によって精製および分析し、質量分析装置(HP 1100シリーズ LC/MSD、Hewlett-Packard社製、ローズビル、米国)を使用して同定した。
配列番号1〜9の前記ペプチド断片を、1Mの濃度になるようにリン酸緩衝食塩水(PBS)にそれぞれ溶解した。得られたタンパク質溶液を以下の試験例で使用した。
β−カテニンの活性化は、Wntシグナル伝達経路において重要な役割を果たしているが、このβ−カテニンの活性化に対する本発明のペプチド断片の効果をin situ近接ライゲーションアッセイにより評価した。この評価は、市販キットであるDUOLINK II in situキット(Olink Bioscience社製、スウェーデン)を用いて行った。
β−カテニンの発現およびGSK−3のリン酸化は、Wntシグナル伝達経路の活性化において重要な役割を果たしているが、β−カテニンの発現およびGSK−3のリン酸化に対する本発明のペプチド断片の効果をウエスタンブロッティングアッセイにより評価した。6ウェルマイクロプレートの各ウェルに2mlのDMEMを入れ、ヒト表皮メラノサイト(Cascade Biologics社製、#C-0245C;ポートランド、オレゴン州、米国)を加えた(1ウェル当たり1.5×105個の細胞)。細胞を5%CO2インキュベーターにおいて37℃で24時間培養して安定化させた。メラノサイト刺激ホルモンであるα−MSH(Sigma社製、ミズーリ州、米国)と、所定の濃度の本発明のペプチド断片(配列番号8のペプチド)とを各ウェルに加えた。細胞を48時間培養した後、細胞からタンパク質を抽出した。得られた抽出物を、抗β−カテニン抗体(Santa Cruz社製、カリフォルニア州、米国)および抗pGSK−3抗体(Cell Signaling Technology社製、マサチューセッツ州、米国)を用いたウエスタンブロッティングアッセイに供し、β−カテニンの発現レベルおよびGSK−3のリン酸化レベルを測定した。この結果を図2に示す。図2に示すように、β−カテニンの発現レベルおよびGSK−3のリン酸化レベルは、配列番号8のペプチドによって濃度依存的に減少した。したがって、本発明のペプチド断片は、メラノサイトにおいてWntシグナル伝達経路を抑制できることが分かる。
6ウェルマイクロプレートの各ウェルに、B16F10細胞(韓国細胞株バンク、ソウル)(1ウェル当たり1.5×105個の細胞)と2mlのDMEMとを加え、5%CO2インキュベーターにおいて37℃で24時間培養した。α−MSH(Sigma社製、ミズーリ州、米国)(100nM)を各ウェルに加え、最終濃度が0.1μM、1μMまたは10μMとなるように配列番号8のペプチドを各ウェルに加えた。α−MSH(100nM)およびアルブチン(0.01%)でそれぞれ処理した群を陽性対照群として用いた。細胞を24時間さらに培養した後、各培養物の写真を撮影し、それぞれのメラニン形成量を比較した。
本発明のペプチド断片がチロシナーゼ活性を抑制するかどうかを評価した。24ウェルプレートの各ウェルに、B16F10細胞(韓国細胞株バンク、ソウル)(1ウェル当たり5×104個の細胞)と1mlのDMEMとを加え、5%CO2インキュベーターにおいて37℃で24時間培養して安定化させた。メラノサイト刺激ホルモンであるα−MSH(Sigma社製、ミズーリ州、米国)と、所定の濃度の配列番号8のペプチドとを各ウェルに加えた。細胞を72時間培養した後、細胞からタンパク質を抽出した。得られた抽出物を96ウェルプレートの各ウェルに加え(1ウェル当たり30g)、L−ジヒドロキシフェニルアラニン(L−DOPA)溶液(100μL)を用いて37℃で2時間処理した。α−MSH(100nM)およびアルブチン(0.01%)でそれぞれ処理した群を陽性対照群として用いた。2時間後、各培養物の写真を撮影し、マイクロリーダーを用いて培養物のチロシナーゼ活性を490nmで測定した。
ヒト表皮メラノサイトにおけるメラニン生成酵素のタンパク質発現に対する本発明のペプチド断片の効果を、ウエスタンブロッティングアッセイを用いて評価した。6ウェルマイクロプレートの各ウェルに、ヒト表皮メラノサイト(Cascade Biologics社製、#C-0245C;ポートランド、オレゴン州、米国)(1ウェル当たり1.5×105個の細胞)と2mlのDMEMとを加え、5%CO2インキュベーターにおいて37℃で24時間培養して安定化させた。メラノサイト刺激ホルモンであるα−MSH(Sigma社製、ミズーリ州、米国)と、所定の濃度の本発明のペプチド断片(配列番号8のペプチド)とを各ウェルに加えた。細胞を24時間培養した後、細胞からタンパク質を抽出した。得られた抽出物を、抗MITF抗体(Abcam社製、マサチューセッツ州、米国)、抗チロシナーゼ抗体(Santa Cruz社製、カリフォルニア州、米国)、抗TRP−1抗体(Santa Cruz社製、カリフォルニア州、米国)および抗TRP−2抗体(Santa Cruz社製、カリフォルニア州、米国)を用いたウエスタンブロッティングアッセイに供し、MITF、チロシナーゼ、TRP−1およびTRP−2の発現レベルを測定した。この結果を図5に示す。図5に示すように、MITF、チロシナーゼ、TRP−1およびTRP−2の発現レベルは、配列番号8のペプチドによる処理によって濃度依存的に減少した。したがって、本発明のペプチド断片は、ヒト表皮メラノサイトにおいて、MITF、チロシナーゼ、TRP−1およびTRP−2の合成を抑制することが分かる。
本発明のペプチド断片が、メラニン生成酵素の遺伝子発現を抑制するかどうかを評価した。6ウェルプレートの各ウェルに、ヒト表皮メラノサイト(1ウェル当たり1.5×105個の細胞)と2mlのDMEMとを加え、5%CO2インキュベーターにおいて37℃で24時間培養して安定化させた。メラノサイト刺激ホルモンであるα−MSH(Sigma社製、ミズーリ州、米国)と、所定の濃度の配列番号8のペプチドとを各ウェルに加えた。細胞を72時間培養した後、細胞から全RNAを抽出し、cDNAを合成した。cDNAの合成は、Reverse Transcription Master Premix(Elpis Biotech社製、テジョン、大韓民国)を用いて行った。合成された各cDNAを鋳型として使用し、ROTOR Q GENE装置を用いて逆転写ポリメラーゼ連鎖反応(RT−PCR)を行った。RT−PCRに使用したプライマーセットを以下の表2に示す。各RT−PCR溶液は、1μlのcDNA、10μlのTOPreal qRT-PCR2X Premix(Enzynomics社製、テジョン、大韓民国)、2μlのプライマーセット(10pmol)および7μlの蒸留水を混合することによって調製した。RT−PCRは、最初に94℃で10分間;次いで、94℃で10秒間、58℃で30秒間、および72℃で1分間を40サイクルの条件で行った。
Claims (5)
- 配列番号1〜5および9のペプチドからなる群から選択されるSfrp5(secreted frizzled protein 5)由来ペプチド断片。
- 配列番号1〜9のペプチドからなる群から選択されるSfrp5(secreted frizzled protein 5)由来ペプチド断片を有効成分として含む、皮膚美白用の化粧料組成物。
- 配列番号1〜9のペプチドからなる群から選択されるSfrp5(secreted frizzled protein 5)由来ペプチド断片を有効成分として含む、皮膚色素沈着抑制用の化粧料組成物。
- 前記皮膚色素沈着が、紫外線暴露によって誘導された皮膚色素沈着である、請求項3に記載の化粧料組成物。
- 配列番号1〜9のペプチドからなる群から選択されるSfrp5(secreted frizzled protein 5)由来ペプチド断片を含む、Wntシグナル伝達経路の抑制を研究または分析するための試薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0164481 | 2014-11-24 | ||
KR1020140164481A KR101572606B1 (ko) | 2014-11-24 | 2014-11-24 | Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물 |
PCT/KR2015/012571 WO2016085208A1 (ko) | 2014-11-24 | 2015-11-23 | Sfrp5 유래의 펩타이드 단편 및 이를 포함하는 피부 미백용 화장료 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017536375A JP2017536375A (ja) | 2017-12-07 |
JP6647302B2 true JP6647302B2 (ja) | 2020-02-14 |
Family
ID=54847796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017527690A Active JP6647302B2 (ja) | 2014-11-24 | 2015-11-23 | Sfrp5由来ペプチド断片およびそれを含有する皮膚美白用化粧料組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US9868775B2 (ja) |
EP (1) | EP3225626B1 (ja) |
JP (1) | JP6647302B2 (ja) |
KR (1) | KR101572606B1 (ja) |
WO (1) | WO2016085208A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101841742B1 (ko) | 2015-12-18 | 2018-03-27 | (주)케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
EP3275891A4 (en) * | 2017-02-06 | 2018-08-01 | Caregen Co., Ltd. | Peptide having skin whitening activity, and use thereof |
KR102506219B1 (ko) * | 2017-02-24 | 2023-03-07 | 리포트루, 엘스.엘. | 화장품에 사용하기 위한 펩타이드 및 조성물 |
WO2018199358A1 (ko) | 2017-04-27 | 2018-11-01 | (주)케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
KR102265432B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
KR102352313B1 (ko) | 2021-05-07 | 2022-01-18 | (주)미래씨티 | 신경줄기세포 추출물 유래 미백 활성을 갖는 DKK-1 (dickkopf WNT signaling pathway inhibitor 1)에서 유래된 펩타이드 및 이를 유효성분으로 함유하는 피부 미백용 화장료 조성물 |
WO2024106822A1 (ko) * | 2022-11-18 | 2024-05-23 | (주)케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
WO2024106820A1 (ko) * | 2022-11-18 | 2024-05-23 | (주)케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433470A (zh) * | 1999-10-29 | 2003-07-30 | 启龙股份公司 | 奈瑟球菌的抗原性肽 |
JP2005537245A (ja) * | 2002-06-26 | 2005-12-08 | エントレメッド インコーポレイテッド | タンパク質活性化レセプターのアンタゴニストを含む組成物および方法 |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
CA2554868A1 (en) * | 2004-01-30 | 2005-08-11 | Ace Aps | Use of ace inhibitors and/or angiotensin ii receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing |
EP1951752A4 (en) | 2005-11-30 | 2008-12-31 | Jung Moon Kim | NON-ACTIVATED Wnt INHIBITOR POLYPEPTIDES AND PREPARATION METHOD THEREOF |
WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
PE20081217A1 (es) * | 2006-09-08 | 2008-09-24 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
JP5771833B2 (ja) * | 2010-09-10 | 2015-09-02 | 岡本株式会社 | 核酸、核酸によりコードされるタンパク質、核酸が導入された組換え生物、及び組換え生物により作られるタンパク質 |
KR101796694B1 (ko) | 2010-11-30 | 2017-11-13 | (주)아모레퍼시픽 | 피부 미백 및 탄력 제고 화장료 조성물 |
KR101167285B1 (ko) | 2011-11-18 | 2012-07-23 | 에이앤펩주식회사 | 피부 미백 활성을 갖는 나이아신-펩타이드 및 그의 용도 |
KR101515158B1 (ko) * | 2013-01-30 | 2015-04-24 | (주)에스테위즈 | 다이설파닐 미백 펩티드를 유효성분으로 포함하는 화장품 조성물 |
-
2014
- 2014-11-24 KR KR1020140164481A patent/KR101572606B1/ko active IP Right Grant
-
2015
- 2015-11-23 JP JP2017527690A patent/JP6647302B2/ja active Active
- 2015-11-23 WO PCT/KR2015/012571 patent/WO2016085208A1/ko active Application Filing
- 2015-11-23 US US15/122,833 patent/US9868775B2/en active Active
- 2015-11-23 EP EP15862282.9A patent/EP3225626B1/en active Active
-
2017
- 2017-07-31 US US15/664,277 patent/US10626157B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170073389A1 (en) | 2017-03-16 |
EP3225626A1 (en) | 2017-10-04 |
JP2017536375A (ja) | 2017-12-07 |
WO2016085208A1 (ko) | 2016-06-02 |
KR101572606B1 (ko) | 2015-11-27 |
US20170334965A1 (en) | 2017-11-23 |
EP3225626A4 (en) | 2018-06-20 |
US10626157B2 (en) | 2020-04-21 |
US9868775B2 (en) | 2018-01-16 |
EP3225626B1 (en) | 2020-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6647302B2 (ja) | Sfrp5由来ペプチド断片およびそれを含有する皮膚美白用化粧料組成物 | |
US10267796B2 (en) | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis | |
JP6148676B2 (ja) | 活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用 | |
Wei et al. | Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I | |
Hu et al. | Induction of retinal‐dependent calcium influx in human melanocytes by UVA or UVB radiation contributes to the stimulation of melanosome transfer | |
KR102011957B1 (ko) | Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물 | |
EP3489252B1 (en) | Peptide having anticancer activity, and cancer preventing and treating pharmaceutical composition, functional health food composition and functional cosmetic composition containing same as active ingredient | |
Wang et al. | Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation | |
Kang et al. | A synthetic peptide blocking TRPV1 activation inhibits UV-induced skin responses | |
JP5773872B2 (ja) | 組成物および方法 | |
KR101987354B1 (ko) | 티오레독신 결합단백질 유래 펩타이드 또는 이를 암호화 하는 폴리뉴클레오타이드를 유효성분으로 함유하는 노화 줄기세포의 역노화용 조성물 및 이의 용도 | |
Wei et al. | TMEM9 mediates IL-6 and IL-1β secretion and is modulated by the Wnt pathway | |
JP2011047932A (ja) | エンプリンとs100a9の結合の阻害を指標とする慢性炎症抑制剤又は癌転移抑制剤のスクリーニング方法 | |
KR20080100333A (ko) | Lox 단백질과 nrage 단백질 사이의 정상적인동시발현 및 상호작용을 복구시키기 위한 물질 | |
Bielig et al. | A function for AAMP in Nod2-mediated NF-κB activation | |
Wang et al. | MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL‐Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway | |
KR20110069059A (ko) | 피부 또는 헤어의 색소침착 연구 또는 조절에 유용한 방법, 화장 관리 방법 및 조성물용 식물 추출물 | |
US9933436B2 (en) | Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator | |
JPWO2012144080A1 (ja) | 皮膚バリア機能改善剤 | |
Shin et al. | The expression pattern and functional role of REIC/Dkk-3 in the development of cutaneous squamous cell carcinoma | |
JP7471085B2 (ja) | コレステロール合成促進剤 | |
US20050215509A1 (en) | Method for inhibiting jnk-1 kinase activity by SCCA | |
Ho et al. | Ohwia caudata aqueous extract attenuates senescence in aging adipose-derived mesenchymal stem cells | |
KR20140141200A (ko) | Rsk2 억제제를 포함하는 피부암 예방 또는 치료용 약학 조성물 | |
KR101457371B1 (ko) | 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170712 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181105 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190828 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6647302 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |